Sponsor

Nuvectis Pharma, Inc.

Clinical research sponsor

Published trials3

Recruiting shown2

Roles1

SourceClinicalTrials.gov

Clinical trials

3 shown

Study of NXP900 With Lorlatinib in ALK+ Lung CancerNCT07784959 · lead sponsor · 2026-08-17

RECRUITING

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerNCT07315113 · lead sponsor · 2025-12-18

RECRUITING

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersNCT05873686 · lead sponsor · 2023-10-26

ACTIVE_NOT_RECRUITING

Sponsor roles

lead sponsor3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.